Samyang Biopharm surged to its daily limit early in the trading session. Following a significant rise in Moderna's stock price due to the successful results of a Phase 3 clinical trial for its mRNA cancer treatment, investors flocked to Samyang Biopharm, which is considered a related stock.
As of 9:10 a.m. on the Korea Exchange, Samyang Biopharm's shares were trading at 56,200 won, up 12,900 won (29.79%) from the previous trading day.
On the New York Stock Exchange, Moderna announced that its patient-specific mRNA cancer treatment, developed in collaboration with Merck, successfully reduced the risk of cancer recurrence and metastasis in high-risk melanoma patients during a Phase 3 trial, leading to a staggering 177% increase in its stock price.
The positive results from the large-scale Phase 3 trial for the personalized mRNA cancer treatment have heightened market expectations for mRNA-based cancer therapies.
Samyang Biopharm is classified as a related stock in the domestic market due to its pipeline for mRNA-based cancer vaccines and its gene delivery system platform.
The company's gene delivery platform, SENS (Selectivity Enabling Nano Shell), utilizes biodegradable polymers and ionic lipids to deliver drugs for gene therapies. It is also conducting research and development on mRNA cancer vaccines, including SYP-2135.
Additionally, the company bolstered investor sentiment with the announcement of its research results prior to the market opening. Samyang Biopharm revealed that a paper detailing the non-clinical research results of its gene delivery system 'NanoReady,' which can be used for mRNA cancer vaccines, was published in the international journal 'Journal of Controlled Release.'
NanoReady, part of the SENS platform, is a nanoparticle delivery system that combines self-developed lipids and biodegradable polymers. It is designed to selectively deliver mRNA to dendritic cells in the spleen, allowing for the production of personalized cancer vaccines containing antigen information tailored to individual cancer characteristics, according to the company.
Building on this research achievement, Samyang Biopharm plans to advance the development of its own mRNA cancer vaccine pipeline while also expanding its platform business through global technology transfers and joint drug development.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.